Statements (53)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
autoimmune disease
neurological disorder |
| gptkbp:affects |
central nervous system
|
| gptkbp:associatedWith |
autoantibodies
oligoclonal bands in CSF |
| gptkbp:cause |
unknown
disability |
| gptkbp:characterizedBy |
inflammation
demyelination neurodegeneration |
| gptkbp:commonIn |
gptkb:women
|
| gptkbp:diagnosedBy |
clinical evaluation
MRI evoked potentials lumbar puncture |
| gptkbp:firstDescribed |
1868
|
| gptkbp:hasNoCure |
true
|
| https://www.w3.org/2000/01/rdf-schema#label |
Multiple Sclerosis
|
| gptkbp:ICD-10_code |
G35
|
| gptkbp:MeSH_ID |
D009103
|
| gptkbp:monitors |
MRI
|
| gptkbp:namedFor |
gptkb:Jean-Martin_Charcot
|
| gptkbp:OMIM |
126200
|
| gptkbp:onset |
young adults
20-40 years old |
| gptkbp:prevalence |
2.8 million people worldwide
|
| gptkbp:prognosis |
variable
|
| gptkbp:researchInterest |
immunomodulation
remyelination |
| gptkbp:riskFactor |
gptkb:Epstein-Barr_virus_infection
smoking genetic predisposition vitamin D deficiency |
| gptkbp:symptom |
pain
fatigue muscle weakness spasticity bladder dysfunction cognitive impairment difficulty with coordination numbness vision problems |
| gptkbp:treatment |
disease-modifying therapies
physical therapy corticosteroids immunosuppressants symptomatic treatments |
| gptkbp:type |
gptkb:primary_progressive_MS
gptkb:progressive-relapsing_MS gptkb:relapsing-remitting_MS gptkb:secondary_progressive_MS |
| gptkbp:bfsParent |
gptkb:MS
|
| gptkbp:bfsLayer |
4
|